Register for email alerts and news feeds:
This journal | BMJ Group
rss
Gut 2005;54:479-487; doi:10.1136/gut.2004.044370
Copyright © 2005 BMJ Publishing Group Ltd & British Society of Gastroenterology.

INFLAMMATORY BOWEL DISEASE

The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss

A R Moschen1,*, A Kaser1,*, B Enrich1, O Ludwiczek1, M Gabriel2, P Obrist3, A M Wolf1, H Tilg1

1 Division of Gastroenterology and Hepatology, Department of Medicine, University Hospital Innsbruck, Innsbruck, Austria
2 Department of Nuclear Medicine, University Hospital Innsbruck, Innsbruck, Austria
3 Department of Pathology, University Hospital Innsbruck, Innsbruck, Austria

Correspondence to:
Correspondence to:
Dr H Tilg
Department of Medicine, University Hospital Innsbruck, Anichstr 35, 6020 Innsbruck, Austria; Herbert.Tilg{at}uibk.ac.at

Background and aims: A substantial proportion of patients with inflammatory bowel disease (IBD) develops osteopenia and osteoporosis in the course of disease. Recent data from a mouse model of colitis suggest that the receptor activator of nuclear factor kappa B (RANKL)/osteoprotegerin (OPG) system may be responsible for bone loss.

Methods: We investigated the activation state of the RANKL/OPG system and its association with bone loss in human IBD. Plasma levels of OPG and RANKL were correlated with bone mineral density and current IBD therapy. Colonic secretion of OPG and RANKL and cell types responsible for such secretion were determined.

Results: OPG plasma levels were elevated 2.4-fold in Crohn’s disease (CD) and 1.9-fold in ulcerative colitis (UC) whereas soluble RANKL (sRANKL) levels were not significantly different in IBD patients compared with healthy controls. High levels of OPG were released from colonic explant cultures (CEC) derived from inflamed IBD specimens, and colonic macrophages and dendritic cells costained for OPG. sRANKL levels from CEC were low both in IBD patients and healthy controls. Interestingly, increased expression of RANKL was mainly confined to cells in the lamina muscularis. A significant negative correlation was found between OPG plasma levels and femoral neck/lumbar spine bone mineral density.

Conclusions: We have demonstrated that IBD is associated with alterations in the RANKL/OPG system. Applying results from a murine model of colitis associated bone loss, the constellation of OPG and sRANKL regulation observed in our study raises the possibility that RANKL/OPG may contribute to the development of bone loss in IBD.

Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa B; sRANKL, soluble receptor activator of nuclear factor kappa B; BMD, bone mineral density; mAb, monoclonal antibody; pAb, polyclonal antibody; CEC, colonic explant culture; TNF, tumour necrosis factor; IL, interleukin; ELISA, enzyme linked immunosorbent assay

Keywords: Crohn’s disease; ulcerative colitis; inflammatory bowel disease; osteoprotegerin; receptor activator of nuclear factor kappa B; bone mineral density


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Digest
Robin Spiller
Gut 2005 54: 443. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Totsuka, T., Kanai, T., Nemoto, Y., Tomita, T., Okamoto, R., Tsuchiya, K., Nakamura, T., Sakamoto, N., Akiba, H., Okumura, K., Yagita, H., Watanabe, M. (2009). RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4+CD25+ Regulatory T Cells in Chronic Colitis. J. Immunol. 182: 6079-6087 [Abstract] [Full Text]  
  • Lorenzo, J., Horowitz, M., Choi, Y. (2008). Osteoimmunology: Interactions of the Bone and Immune System. Endocr. Rev. 29: 403-440 [Abstract] [Full Text]  
  • Tilg, H, Moschen, A R, Kaser, A, Pines, A, Dotan, I (2008). Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57: 684-694 [Abstract] [Full Text]  
  • Nakchbandi, I. A., Lang, R., Kinder, B., Insogna, K. L. (2008). The Role of the Receptor Activator of Nuclear Factor-{kappa}B Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. J. Clin. Endocrinol. Metab. 93: 967-973 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Chronic inflammatory intestinal diseases and bone loss
Maria Teresa Bardella, et al.
Gut Online, 26 Apr 2005 [Full text]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Cardiology Jobs

Gastroenterology Jobs